In 2021, the biologics CDMO secondary packaging market was worth around USD 1,711.7 million, and it is projected to advance at a 8.7% CAGR from 2021 to 2030, hitting USD 3,622.6 million in 2030, according to P&S Intelligence.
 |
| To learn more about this report: https://bit.ly/3m2cE5M |
This development can be ascribed to the rising pharmaceutical market, snowballing making of drugs, and the increasing occurrence of numerous diseases, such as infectious diseases, chronic diseases, and hereditary disorders.
Biopharmaceutical businesses are projected to introduce numerous new products, such as treatments for diseases, to fulfill important unmet medical requirements. Also, above 7,800 products in medical development span an extensive variety of therapeutic areas, such as cardiovascular, cancer, neurology, diabetes, and others, because of the huge expenditure in research and development.
In 2021, on the basis of primary package types, blister packs held for the biologics CDMO secondary packaging market's largest share of approximately 40%, and also projected to show the highest CAGR in the coming few years. This is due to they utmost significant king of packaging boxes for which the main part of the CDMOs offer secondary packaging services. Blister packing is a feasible solution for the sensitive nature of biologics, because of its adaptability and transparency.
North America held the largest market share, of above, 40%, in 2021. This is mainly because of the increasing outsourcing of drug research and development and manufacturing actions by biopharma companies.
Numerous businesses are wishing to team up with skilled packing providers that offer up-to-date packaging solutions and have the vital capabilities to create unique packing designs in a lucrative and time-efficient manner.
The APAC industry is projected to experience the fastest development in the coming few years. Mainly because of the increasing occurrence of chronic diseases, the growing concentration of businesses on contract engineering, and key players showing robust attention to facility extension in the APAC.
Hence, the rising pharmaceutical market, snowballing making of drugs, and the increasing occurrence of numerous diseases, such as infectious diseases, chronic diseases, and hereditary disorders, are the major factors, contributing to the growth of the biologics CDMO secondary packaging industry.
